Robert G Petit

US Patent:

20020147156, Oct 10, 2002

Filed:

Nov 14, 2001

Appl. No.:

09/993465

Inventors:

Robert Petit - Newtown PA, US
Edward Shinal - Pennington NJ, US

International Classification:

A61K031/70
A01N061/00

US Classification:

514/023000, 514/001000

Abstract:

Provided is a composition and a method for increasing cellular uptake of bioactive agents, particularly those compounds termed “small molecules” into the cells of mammalian tissue, such as the epithelial cells of the mucosa.

US Patent:

20040176319, Sep 9, 2004

Filed:

Mar 9, 2004

Appl. No.:

10/796261

Inventors:

Robert Petit - Newtown PA, US
Esward Shinal - Pennington NJ, US

Assignee:

Aesgen, Inc.

International Classification:

A61K031/7012
A61K031/198
A61K031/045

US Classification:

514/053000, 514/563000, 514/728000

Abstract:

Provided is a composition and a method for increasing cellular uptake of bioactive agents, particularly those compounds termed “small molecules” into the cells of mammalian tissue, such as the epithelial cells of the mucosa.

US Patent:

20060121091, Jun 8, 2006

Filed:

Oct 21, 2005

Appl. No.:

11/255771

Inventors:

Robert Petit - Newtown PA, US
Edward Shinal - Pennington NJ, US

International Classification:

A61K 31/198
A61K 9/68

US Classification:

424440000, 514563000

Abstract:

Provided is a composition and a method for increasing cellular uptake of bioactive agents, particularly those compounds termed “small molecules” into the cells of mammalian tissue, such as the epithelial cells of the mucosa.

US Patent:

20190248856, Aug 15, 2019

Filed:

Jun 30, 2017

Appl. No.:

16/315082

Inventors:

- Princeton NJ, US
Robert Petit - Newtown PA, US

Assignee:

Advaxis, Inc. - Princeton NJ

International Classification:

C07K 14/47
C07K 14/195
A61K 39/39
A61K 39/00
A61P 35/00

Abstract:

Provided are -based immunogenic compositions comprising Wilms tumor protein (WT1) antigens and methods for treating and vaccinating against cancer and inducing an immune response against the same in a subject. Also provided herein are recombinant fusion polypeptides or chimeric polypeptides comprising Wilms tumor protein antigens, nucleic acids encoding such chimeric polypeptides or fusion polypeptides, recombinant bacteria or strains comprising such chimeric polypeptides or fusion polypeptides or such nucleic acids, and cell banks comprising such recombinant bacteria or strains. Also provided herein are methods of generating such chimeric polypeptides or fusion polypeptides, such nucleic acids, and such recombinant bacteria or strains. Also provided are immunogenic compositions, pharmaceutical compositions, and vaccines comprising such chimeric polypeptides or fusion polypeptides, such nucleic acids, or such recombinant bacteria or strains. Also provided are methods of inducing an anti-WT1 immune response in a subject, methods of inducing an anti-WT1-expressing-tumor or anti-WT1-expressing-cancer immune response in a subject, methods of treating a WT1-expressing or WT1-associated tumor or cancer in a subject, methods of preventing a WT1-expressing or WT1-associated tumor or cancer in a subject, and methods of protecting a subject against a WT1-expressing or WT1-associated tumor or cancer using such recombinant chimeric polypeptides or fusion polypeptides, nucleic acids, recombinant bacteria or strains, immunogenic compositions, pharmaceutical compositions, or vaccines.

US Patent:

20180104284, Apr 19, 2018

Filed:

May 12, 2016

Appl. No.:

15/573382

Inventors:

- Princeton NJ, US
Poonam Molli - North Brunswick NJ, US
Robert Petit - Newtown PA, US

International Classification:

A61K 35/74
A61K 39/00
C07K 14/195
C12N 1/36
C07K 16/12

Abstract:

The present invention relates to compositions comprising a recombinant attenuated strain expressing a truncated ActA and fusion proteins thereof and methods of using the same for inducing anti-disease immune responses, and treatment of the same, including a tumor growth or cancer. In particular, the invention relates to the treatment of a tumor growth or cancer using a live attenuated recombinant strain that expresses a fusion protein of a truncated ActA fused to an antigen.

US Patent:

20170106072, Apr 20, 2017

Filed:

Feb 18, 2015

Appl. No.:

15/119661

Inventors:

- Princeton NJ, US
Robert PETIT - Newtown PA, US

Assignee:

Advaxis, Inc. - Princeton NJ

International Classification:

A61K 39/02
C07K 14/195
A61K 45/06
A61K 39/00
C12Q 1/68
G01N 33/574

Abstract:

This invention provides methods and compositions for using evaluating biomarker expression in a disease and providing a multi-targeted -based immunotherapeutic approach against said disease. In a related aspect, the invention relates to a method of treating a disease in a subject, the method comprising the steps of: a. obtaining a biological sample from said subject; b. evaluating the expression of a predetermined number of biomarkers in said biological sample; c. administering to said subject a composition comprising a recombinant strain, said strain comprising a nucleic acid sequence encoding at least one fusion protein, wherein said fusion protein comprises a biomarker identified in said biological sample, wherein said biomarker is associated with said disease, wherein said biomarker is fused to a PEST-containing polypeptide, and wherein each fusion protein within said comprises a different biomarker, thereby treating said disease in said subject.